Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma

Leukemia
Georg HessMartin Dreyling

Abstract

In this phase I/II study, we explored the combination of Temsirolimus with Bendamustine and Rituximab (BeRT) in patients with r/r follicular lymphoma (FL) or mantle cell lymphoma (MCL). Patients with 1-3 prior therapies received Bendamustine (90 mg/m(2), day 1+2) and Rituximab (375 mg/m(2), day 1) with Temsirolimus in doses from 25 to 75 mg added on day 1, 8, 15 of a 28-day cycle. Fifteen (11 MCL, 4 FL) patients were included in the phase I. Median age was 73 years and median pretreatment number was 2. No formal dose-limiting toxicity was observed. Dominant non-hematological side effects were fatigue in 11 (73%), nausea in 9 (60%), mucositis in 7 (47%) and vomiting in 6 patients (40%). Cough, diarrhea, pyrexia and rash were observed in five patients (33%) each. Grade 3/4 events included leukopenia in 6 (40%), neutropenia in 4 (27%) and thrombocytopenia in 2 patients (13%). An objective response was observed in 14/15 patients (93%), including 5 complete response (33%; all MCL). After a median follow-up of 19 months, 67% of patients are without signs of progression. Temsirolimus can be safely added to BR with promising preliminary activity. Recruitment in phase II is ongoing.

References

Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mathias J RummelParis S Mitrou
Jun 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas E WitzigScott H Kaufmann
Sep 27, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard I FisherAndré Goy
Oct 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Manuel HidalgoEric K Rowinsky
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Feb 5, 2008·Expert Reviews in Molecular Medicine·Elias DrakosL Jeffrey Medeiros
Jul 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K Sue RobinsonBruce D Cheson
Mar 6, 2009·Leukemia Research·Sherif S FaragMichael R Grever
Jul 8, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Georg HessBertrand Coiffier
Sep 11, 2010·Journal of Hematology & Oncology·Li WangAnne Janin
Sep 15, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sonali M SmithBarbara Pro
Nov 19, 2010·Expert Review of Hematology·Georg Hess
Jan 14, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T E WitzigM S Czuczman
Aug 2, 2011·Nature Genetics·Laura PasqualucciRiccardo Dalla-Favera
Feb 9, 2012·Haematologica·Christoph RennerUNKNOWN Swiss SAKK and French GOELAMS group from European Mantle Cell Lymphoma Network
Aug 10, 2012·The New England Journal of Medicine·H C Kluin-NelemansM H Dreyling
Oct 10, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ranjana H AdvaniNathan H Fowler
Feb 13, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carlo ViscoFrancesco Rodeghiero
Jun 21, 2013·The New England Journal of Medicine·Michael L WangKristie A Blum
Jan 24, 2014·The New England Journal of Medicine·Ajay K GopalGilles A Salles

❮ Previous
Next ❯

Citations

Feb 18, 2016·Der Internist·M DreylingE Hoster
Dec 15, 2015·Annals of Hematology·Anna-Katharina ZoellnerMartin Dreyling
Aug 30, 2016·Expert Opinion on Drug Discovery·Magdalena WitkowskaTadeusz Robak
Feb 2, 2017·British Journal of Haematology·Teresa Calimeri, Andrés J M Ferreri
Mar 16, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Agnieszka KorfelPhilipp Kiewe
Apr 14, 2017·Hematology/oncology and Stem Cell Therapy·Jose D Sandoval-SusBijal D Shah
Jun 27, 2017·Cancer Treatment Reviews·Peter MartinMartin Dreyling
Nov 28, 2017·Leukemia & Lymphoma·Martin DreylingPier Luigi Zinzani
Dec 6, 2017·Therapeutic Advances in Hematology·Trent Peng WangStefan Klaus Barta
Apr 26, 2019·Leukemia & Lymphoma·Tadeusz RobakMartin Dreyling
Feb 9, 2019·Experimental Hematology & Oncology·Abdullah LadhaJeffrey J Pu
Nov 19, 2019·Expert Opinion on Pharmacotherapy·Fortunato MorabitoMassimo Gentile
Aug 28, 2020·Expert Opinion on Therapeutic Targets·Pavel Klener

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.